tiprankstipranks
Trending News
More News >
CalciMedica (CALC)
NASDAQ:CALC
US Market
Advertisement

CalciMedica (CALC) Drug Pipeline

Compare
284 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Auxora
Acute Kidney Injury
Phase II
Recruiting
A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk"
Apr 16, 2024
Cm-4620 Injectable Emulsion Or Cm-4620-Ie
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
Phase II
Completed
A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS
Dec 15, 2020
Auxora (Part 1), Standard Of Care (Part 1), Auxora (Part 2)
Pneumonia
Phase II
Completed
A Study of Auxora in Patients With Severe COVID-19 Pneumonia
Apr 07, 2020

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does CalciMedica (CALC) have in its pipeline
      CALC is currently developing the following drugs: Auxora, Cm-4620 Injectable Emulsion Or Cm-4620-Ie, Auxora (Part 1), Standard Of Care (Part 1), Auxora (Part 2). These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis